Belinostat

CAS No. 414864-00-9

Belinostat ( PXD101 )

Catalog No. M14420 CAS No. 414864-00-9

Belinostat is a novel hydroxamic acid-type histone deacetylase (HDAC) inhibitor with antineoplastic activity.

Purity : >98%(HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 35 In Stock
10MG 56 In Stock
25MG 88 In Stock
50MG 132 In Stock
100MG 195 In Stock
200MG 312 In Stock
500MG 520 In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    Belinostat
  • Note
    Research use only, not for human use.
  • Brief Description
    Belinostat is a novel hydroxamic acid-type histone deacetylase (HDAC) inhibitor with antineoplastic activity.
  • Description
    Belinostat is a novel hydroxamic acid-type histone deacetylase (HDAC) inhibitor with antineoplastic activity. Belinostat targets HDAC enzymes, thereby inhibiting tumor cell proliferation, inducing apoptosis, promoting cellular differentiation, and inhibiting angiogenesis. This agent may sensitize drug-resistant tumor cells to other antineoplastic agents, possibly through a mechanism involving the down-regulation of thymidylate synthase.
  • Synonyms
    PXD101
  • Pathway
    Cell Cycle/DNA Damage
  • Target
    HDAC
  • Recptor
    HDAC
  • Research Area
    Cancer
  • Indication
    ——

Chemical Information

  • CAS Number
    414864-00-9
  • Formula Weight
    318.35
  • Molecular Formula
    C15H14N2O4S
  • Purity
    >98%(HPLC)
  • Solubility
    DMSO: 64 mg/mL (201.03 mM)
  • SMILES
    C1=CC=C(C=C1)NS(=O)(=O)C2=CC=CC(=C2)/C=C/C(=O)NO
  • Chemical Name
    2-Propenamide, N-hydroxy-3-(3-((phenylamino)sulfonyl)phenyl)-

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.Savickiene J, et al. anticancer Drugs. 2014 Sep;25(8):938-49.
molnova catalog
related products
  • Exifone

    Exifone is a mixed, nonessential activator of HDAC1 that is capable of binding to both free and substrate-bound enzyme, resulting in an increased relative maximal rate of HDAC1-catalyzed deacetylation.

  • Detomidine HCl

    Detomidine HCl produce dose-dependent sedative and analgesic effects, mediatated by activation of α2 catecholamine receptors.

  • PCI-24781

    A broad spectrum HDAC inhibitor; inhibits pure recombinant HDAC1 with Ki of 7 nM.